Compare OBT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | XOMA |
|---|---|---|
| Founded | 1892 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.7M | 471.6M |
| IPO Year | 2021 | N/A |
| Metric | OBT | XOMA |
|---|---|---|
| Price | $33.45 | $41.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $36.00 | ★ $52.50 |
| AVG Volume (30 Days) | 31.0K | ★ 368.0K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 34.82 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | $24.59 |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $39.65 | ★ $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.84 | $22.29 |
| 52 Week High | $37.99 | $42.81 |
| Indicator | OBT | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 66.51 |
| Support Level | $33.25 | $24.46 |
| Resistance Level | $36.64 | $42.15 |
| Average True Range (ATR) | 1.07 | 0.46 |
| MACD | -0.10 | -0.33 |
| Stochastic Oscillator | 32.71 | 69.40 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.